Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
CYRX 
Cryoport Inc (CYRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/24/2026: CYRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $13.22
1 Year Target Price $13.22
| 4 | Strong Buy |
| 2 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 407.56M USD | Price to earnings Ratio - | 1Y Target Price 13.22 |
Price to earnings Ratio - | 1Y Target Price 13.22 | ||
Volume (30-day avg) 10 | Beta 1.68 | 52 Weeks Range 4.58 - 11.45 | Updated Date 02/24/2026 |
52 Weeks Range 4.58 - 11.45 | Updated Date 02/24/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.22 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 29.23% | Operating Margin (TTM) -22.01% |
Management Effectiveness
Return on Assets (TTM) -4.39% | Return on Equity (TTM) -11.3% |
Valuation
Trailing PE - | Forward PE 58.14 | Enterprise Value 309449820 | Price to Sales(TTM) 1.67 |
Enterprise Value 309449820 | Price to Sales(TTM) 1.67 | ||
Enterprise Value to Revenue 1.3 | Enterprise Value to EBITDA -13 | Shares Outstanding 50068904 | Shares Floating 40213341 |
Shares Outstanding 50068904 | Shares Floating 40213341 | ||
Percent Insiders 3.85 | Percent Institutions 96.86 |
Upturn AI SWOT
Cryoport Inc
Company Overview
History and Background
Cryoport, Inc. was founded in 2002 and is a global leader in temperature-controlled logistics solutions. The company has evolved significantly, expanding its service offerings to support the life sciences, biopharma, and advanced therapy markets. Key milestones include strategic acquisitions and continuous innovation in cold chain technology.
Core Business Areas
- Cryoport Express Cryogenic Services: Provides advanced cryogenic temperature-controlled logistics solutions for the biopharmaceutical industry, including cell and gene therapies, stem cells, and reproductive medicine. This includes specialized packaging, global shipping, and real-time temperature monitoring.
- Cryoport Express BioAnalytics: Offers a suite of analytical services to support the biopharmaceutical and life sciences industries, including sample management, biobanking, and laboratory services. This segment aims to provide comprehensive solutions beyond just logistics.
- Cryoport Life Sciences: This segment encompasses the broader range of logistics and support services tailored for the life sciences sector, including clinical trials and research applications.
Leadership and Structure
Cryoport, Inc. is led by a management team with extensive experience in logistics, life sciences, and technology. The company operates with a decentralized structure for its service divisions, fostering specialized expertise while maintaining central oversight.
Top Products and Market Share
Key Offerings
- Cryoport Expressu00ae: A flagship cryogenic shipping solution that utilizes proprietary validated shippers and real-time temperature monitoring technology to ensure the integrity of temperature-sensitive biological materials during transit. Competitors include World Courier (a Cencora company), Cardinal Health, and other specialized logistics providers. Market share data is not publicly disclosed but is a significant portion of the company's revenue.
- SmartVueu00ae Real-Time Temperature Monitoring: An integrated system providing real-time data on temperature, shock, and tilt for shipments, offering enhanced visibility and control throughout the supply chain. This technology is a key differentiator. Competitors offer similar tracking solutions but Cryoport's integration into its core logistics offering is a strength.
- BioServices: A platform of services that includes sample management, biobanking, and laboratory services, complementing its logistics offerings. This is a growing area with competition from specialized biobanking facilities and contract research organizations (CROs).
Market Dynamics
Industry Overview
The temperature-controlled logistics market, particularly for life sciences and biopharmaceutical products, is experiencing robust growth driven by the increasing demand for advanced therapies, biologics, and personalized medicine. The global cold chain market is expected to continue its upward trajectory.
Positioning
Cryoport is positioned as a premium provider of specialized cold chain logistics for high-value, temperature-sensitive biological materials. Its competitive advantages include its proprietary technology, global network, deep expertise in cryogenic solutions, and strong focus on the cell and gene therapy sector.
Total Addressable Market (TAM)
The TAM for temperature-controlled logistics in the life sciences sector is substantial and growing, estimated to be tens of billions of dollars globally. Cryoport is actively addressing a significant portion of this market, particularly in specialized niches like cell and gene therapy logistics, where its expertise is highly valued.
Upturn SWOT Analysis
Strengths
- Leading provider of specialized cryogenic logistics for cell and gene therapies.
- Proprietary SmartVueu00ae real-time monitoring technology.
- Established global network and operational infrastructure.
- Strong relationships within the biopharmaceutical and life sciences industries.
- Acquisition strategy to expand service capabilities.
Weaknesses
- High reliance on a few key customers.
- Capital-intensive nature of maintaining and expanding infrastructure.
- Potential for competitive pricing pressure.
- Integration challenges with acquired companies.
Opportunities
- Continued growth in the cell and gene therapy market.
- Expansion into new geographic regions and therapeutic areas.
- Development of new logistics and bioanalytics solutions.
- Increased demand for end-to-end supply chain solutions.
- Further consolidation within the cold chain logistics sector.
Threats
- Intensifying competition from established and emerging players.
- Regulatory changes impacting logistics and transportation.
- Economic downturns affecting biopharmaceutical R&D and manufacturing.
- Disruptions in global supply chains (e.g., geopolitical events, pandemics).
- Technological advancements by competitors.
Competitors and Market Share
Key Competitors
- World Courier (a Cencora company) (WCG)
- Cardinal Health (CAH)
- Marken (a UPS company)
- PFSweb (now rebranded as PFS)
- Various regional and specialized cold chain logistics providers.
Competitive Landscape
Cryoport's competitive advantage lies in its specialized focus on high-value, temperature-sensitive biological materials, particularly cell and gene therapies, and its proprietary real-time monitoring technology. While larger players like World Courier and Cardinal Health have broader logistics networks, Cryoport differentiates itself with its deep expertise and tailored solutions for niche, rapidly growing segments of the life sciences market.
Major Acquisitions
Cryoport acquired Bio-Analytics
- Year: 2021
- Acquisition Price (USD millions): 136.7
- Strategic Rationale: To expand its service offerings into bioanalytics and sample management, creating a more comprehensive suite of solutions for the life sciences industry beyond just logistics.
Cryoport acquired Movianto
- Year: 2021
- Acquisition Price (USD millions): 280
- Strategic Rationale: To enhance its global footprint and expand its capabilities in clinical trial logistics and specialized pharmaceutical distribution, particularly in Europe.
Growth Trajectory and Initiatives
Historical Growth: Cryoport has experienced significant historical growth, primarily fueled by the burgeoning cell and gene therapy market and strategic acquisitions that expanded its service portfolio and geographic reach.
Future Projections: Future growth is projected to be driven by the continued expansion of the advanced therapy market, increasing demand for specialized cold chain logistics, and the company's ability to secure new partnerships and integrate acquired businesses. Analyst estimates typically anticipate continued revenue growth, though profitability is dependent on managing operational costs and investment cycles.
Recent Initiatives: Recent initiatives include strategic acquisitions to bolster its bioanalytics and supply chain service offerings, expansion of its global logistics network, and continued investment in its SmartVueu00ae technology platform to enhance service offerings and competitive positioning.
Summary
Cryoport Inc. is a leading player in the specialized temperature-controlled logistics market for life sciences, with a strong focus on cell and gene therapies. Its proprietary technology and strategic acquisitions have positioned it for continued growth in this expanding sector. However, the company faces challenges related to intense competition, integration of acquisitions, and the capital-intensive nature of its operations. Close monitoring of its customer concentration and ability to maintain its technological edge will be crucial for its future success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Investor Relations websites (Cryoport Inc.)
- SEC Filings (10-K, 10-Q)
- Financial News and Analysis sites (e.g., Bloomberg, Reuters, Seeking Alpha)
- Industry reports on cold chain logistics and biopharmaceuticals.
Disclaimers:
This JSON output is for informational purposes only and does not constitute financial advice. Data is based on publicly available information and may be subject to change. Market share data is estimated. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cryoport Inc
Exchange NASDAQ | Headquaters Brentwood, TN, United States | ||
IPO Launch date 2005-03-15 | Chairman, President & CEO Mr. Jerrell W. Shelton | ||
Sector Industrials | Industry Integrated Freight & Logistics | Full time employees 1090 | Website https://www.cryoportinc.com |
Full time employees 1090 | Website https://www.cryoportinc.com | ||
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company's Life Sciences Services segment provides temperature-controlled logistics and cryogenic biostorage within the life science industry. Its Life Sciences Products segment offers cryogenic freezers, cryogenic dewars, and accessories within the life science industry through direct sales or a distribution network. The company's products include Cryoport Express Shippers; Cryoport ELITE Shippers; Cryoport Express Cryogenic HV3 Shipping System; Smartpak II Condition Monitoring System and Tec4Med; and Cryoport accessories. It also provides Cryoport BioStorage/Bioservices, such as CRYOGENE, a biostorage solution for the provision of pre-clinical temperature-controlled biological materials management services; and Cryoport Systems Bioservices, including controlled temperature storage, kitting, labelling, fulfillment, sample management, drug return, and Qualified Person drug product release. In addition, the company offers IntegriCell services that comprise apheresis/leukapheresis collection, cryoshuttle transportation, cryo-process optimization, and cryopreservation services; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; CRYOPDP, a temperature-controlled logistics solution; MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; and Vario cryogenic system, a cryogenic freezer system. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. The company was founded in 1999 and is based in Brentwood, Tennessee.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.